<DOC>
	<DOC>NCT02628028</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).</brief_summary>
	<brief_title>A Study of LY3337641 in Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Female subjects test negative for pregnancy at screening and agree not to breastfeed Female subjects: agree to use a reliable method of birth control from the start of screening until 2 weeks after the last dose of study drug or be of nonchildbearing potential Male subjects: agree to use a reliable method of birth control from the start of screening until 2 weeks after the last dose of study drug or have undergone vasectomy Have a diagnosis of RA based on the 2010 ACR/European League against Rheumatism criteria Have at least 1 of the following: rheumatoid factor or anticitrullinated peptide antibodies (ACPA) at screening OR radiographs documenting bony erosions Have active RA, defined as: Part A: ≥3 swollen joints (based on 66joint counts) Part B: ≥6 swollen joints (based on 66joint counts) ≥6 tender joints (based on 68joint counts) hsCRP levels greater than the upper limit of normal (ULN) OR positive for ACPA Part B only: Have had inadequate response, loss of response, or intolerance to at least 1 synthetic OR biologic diseasemodifying antirheumatic drug (DMARD) Have received any of the following: Part B only: any prior treatment with a product directly targeting Bruton's tyrosine kinase (BTK) (marketed or investigational) belimumab, natalizumab, or vedolizumab within 6 months prior to baseline Bcelldepleting agents (such as rituximab) or other celldepleting biologics (eg, antiCD3 antibody) within 12 months prior to screening for Part A or at any time prior to screening for Part B Have known hypogammaglobulinemia Have hepatitis C virus, hepatitis B virus or human immunodeficiency virus Have active tuberculosis (TB) Are at high risk of infection or have recent evidence of clinically significant infection Have had lymphoma, leukemia, or any malignancy within the previous 5 years except for treated basal cell or squamous epithelial carcinomas of the skin Have received a live (attenuated) vaccine within 28 days prior to baseline or plan to receive one during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>